BDBM397353 US10596172, Compound I-221::US10828300, Compound I-221::US11351168, Compound I-221::US9987276, Compound I-221

SMILES C=CC(=O)Nc1cccc(Nc2nc(Nc3ccccc3)ncc2C(=O)NC2CC2)c1

InChI Key InChIKey=FKLZHEFUQKMNLE-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 397353   

TargetTyrosine-protein kinase BTK(Human)
Celgene Car

US Patent
LigandPNGBDBM397353(US9987276, Compound I-221 | US10596172, Compound I...)
Affinity DataIC50: 55nMAssay Description:Briefly, 10× stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13×ATP (AS001A) and ap...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397353(US9987276, Compound I-221 | US10596172, Compound I...)
Affinity DataIC50: 55nMAssay Description:Briefly, 10× stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13×ATP (AS001A) and ap...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Celgene Car

US Patent
LigandPNGBDBM397353(US9987276, Compound I-221 | US10596172, Compound I...)
Affinity DataIC50: 55nMAssay Description:Briefly, 10× stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13×ATP (AS001A) and ap...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/28/2021
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397353(US9987276, Compound I-221 | US10596172, Compound I...)
Affinity DataIC50: 55nMAssay Description:EGFR (WT) and EGFR (T790M/L858R): The Omnia Assay Protocol for potency assessment against EGFR is performed as described in Example 251 above except ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Celgene Car

US Patent
LigandPNGBDBM397353(US9987276, Compound I-221 | US10596172, Compound I...)
Affinity DataIC50: 550nMAssay Description:Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13×ATP (AS001A) and ap...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Celgene Car

US Patent
LigandPNGBDBM397353(US9987276, Compound I-221 | US10596172, Compound I...)
Affinity DataIC50: 550nMAssay Description:Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13×ATP (AS001A) and ap...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent